Amaurosis fugax, transient monocular loss of vision, like transient cerebral ischemic attack (TIA), heralds the future onset of stroke, with 9% and 12%, respectively, of patients with amaurosis fugax and TIA having a major cardiovascular event (stroke, myocardial infarction, cardiovascular-related death) over a 4-year follow-up period (1). Amaurosis fugax is most commonly caused by emboli from ipsilateral carotid artery plaque or, less commonly, by atrial fibrillation, or by cardiac thrombi (2-6). Vasospasm (7), giant cell arteritis (8), systemic lupus erythematosus, and high levels of anticardiolipin antibodies (9,10) may also cause amaurosis fugax. To date, there have been no systematic examinations of inherited thrombophilia and/or hypofibrinolysis as potential etiologies for amaurosis fugax. Confirmation of causal relationships between heritable and acquired thrombophilia-hypofibrinolysis and amaurosis fugax, accompanied Summary: The aim of this study was to prospectively assess associations between amaurosis fugax, inherited thrombophilia, and acquired thrombophilia. Thrombophilia and hypofibrinolysis were studied in 11 cases (eight women, three men; all white) with amaurosis fugax, 57 ± 17 years old, selected by the absence of abnormal brain magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), magnetic resonance venography (MRV), ipsilateral internal carotid artery plaque, atrial fibrillation, or cardiac thrombus. Cases were compared to 78 healthy adult white controls (53 ± 18 years old) for serologic measures, and by polymerase chain reaction to 248 healthy white controls (78 adults, 170 children) for gene mutations. All 11 cases had one or more familial thrombophilic coagulation disorder including one heterozygous for the G1691A factor V Leiden mutation, two with low free protein S, four with high factor VIII, three with resistance to activated protein C, three homozygous for the C677T methylenetetrahydrofolate reductase (MTHFR) mutation, two compound C677T-A1298C MTHFR heterozygotes, and three with hypofibrinolytic 4G4G homozygosity for the PAI-1 gene. The case with factor VIII of 160% had two other thrombophilias (compound MTHFR C677T-A1298C heterozygosity, resistance to activated protein C), and hypofibrinolytic high Lp(a). Thrombophilic C677T MTHFR homozygosity or compound C677T-A1298C heterozygosity was present in five of 10 (50%) cases vs. 30 of 248 (12%) controls, Fisher's p (p f ) = .005. Thrombophilic factor VIII was high in four of 10 (40%) cases vs. 0 of 38 controls, p f = .001. Thrombophilic hyperestrogenemia in five of the eight women (four exogenous estrogen, one pregnant) may have interacted with inherited thrombophilia-hypofibrinolysis, promoting thrombus formation. In cases selected by the absence of abnormal brain magnetic resonance imaging, significant ipsilateral internal carotid artery plaque, atrial fibrillation, or cardiac thrombus, we speculate that amaurosis fugax can be caused by reversible (by anticoagulation) retinal artery thrombi associated with heritable thrombophilia and/or hypofibrinolysis, often augmented by estrogen-driven acquired thrombophilia.
by better understanding of the molecular genetic causes of thrombosis, should facilitate amaurosis fugax prevention and thromboprophylaxis (11) . The association of amaurosis fugax with hypofibrinolysis and thrombophilia also has broad clinical implications, because these coagulation disorders can cause preventable/reversible non-arteritic ischemic optic neuropathy, central retinal vein thrombosis, deep vein thrombosis, pulmonary embolism, ischemic cerebral vascular accidents, myocardial infarctions, major complications of pregnancy, pseudotumor cerebri, and osteonecrosis (12) (13) (14) (15) (16) (17) (18) (19) . In this report, we prospectively assessed associations between amaurosis fugax and inherited and acquired thrombophilia in 11 cases selected by the absence of abnormal brain magnetic resonance imaging, ipsilateral internal carotid artery plaque, atrial fibrillation, or cardiac thrombus.
PATIENTS AND METHODS

Study Design, Cases
The study was carried out following a protocol approved by the Jewish Hospital institutional review board, with signed informed consent. To enter the study, cases were required to have been diagnosed by ophthalmologists as having amaurosis fugax with transient monocular loss of vision (5) . Cases were selected by the absence of abnormal brain magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), magnetic resonance venography (MRV), atrial fibrillation, or cardiac thrombus (by echocardiography), and were required to have carotid and vertebral duplex imaging examinations that were negative for ipsilateral, hemodynamically significant atherosclerotic plaque. MRI, MRV, MRA, and carotid and vertebral duplex imaging were carried out in the Alliance Hospitals' Vascular Laboratories and Diagnostic Imaging divisions. Electrocardiograms and echocardiography were done in the Alliance Hospitals' cardiology division.
The 11 cases who met the above exclusion criteria were referred to the outpatient Cholesterol Center from three ophthalmology practices and were prospectively enrolled in the study in the temporal order of their referral. They had all experienced two or more episodes of transient monocular vision loss (5) (usually <10 minutes duration). At the cases' initial visit to the Cholesterol Center, 21 or more days after their ocular vascular event, a detailed history and physical examination were done. Review of medical history for the following conditions was carried out: connective tissue disease-lupus erythematosus, hypertension, cigarette smoking, estrogen use, diabetes mellitus, pulmonary embolus, deep venous thrombosis, repetitive pregnancy loss, antiphospholipid antibody syndrome, and therapy for hypertension, type II diabetes mellitus, and hyperlipidemia (Table 1) . No patients had taken warfarin or heparin within 3 months of blood sampling. 
Controls
For comparison of serologic measures associated with thrombophilia or hypofibrinolysis (Table 2) (12-21), we used 78 adult white controls, 38 healthy adult hospital personnel (17 men, 21 women), and 40 subjects (17 men, 23 women) sampled before orthopedic surgery. By selection, the 44 female controls were not pregnant and not taking estrogens or oral contraceptives that might affect serologic coagulation measures. Moreover, none of the 78 controls were taking non-hormonal drugs that might affect serologic coagulation measures. The hospital personnel controls were recruited by posted requests for volunteers over a 6-month period that was ante-and post-dated by the 24-month period during which the amaurosis fugax cases were recruited. The orthopedic surgery controls were recruited over the same 24-month period as the cases.
For comparison of mutant or polymorphic genes, 170 healthy white children sampled before same-day surgery (95 male, 72 female, 3 unknown) were added to the 78 adult controls. There were no changes in polymerase chain reaction (PCR) or serologic laboratory procedures during the 36-month period.
Plasma Preparation
Blood was collected in 3.2% buffered sodium citrate (19, 21) . The samples were immediately centrifuged at 2600 g for 15 minutes to obtain platelet-poor plasma. Blood for PCR analysis was drawn in EDTA and the DNA extracted for subsequent analysis (12, 13, (16) (17) (18) (19) (20) .
Coagulation Assays
PCR Assays for five gene mutations: G1691A Leiden mutation in the factor V gene, G20210A mutation of the prothrombin gene, C677T and A1298C mutations of the MTHFR gene, 4G/5G polymorphism of the PAI-1 gene promoter, and the platelet glycoprotein IIb/IIIa (PL A1/A2, thymine to cytosine substitution at position 196) were performed as previously described (Table  2) (12, 13, (16) (17) (18) (19) (20) .
The non-PCR coagulation tests in plasma and serum (12, 13, (16) (17) (18) (19) (20) (21) (Table 2) were performed following previously published methods. The following tests were done in plasma: dilute Russel's Viper Venom time (dRVVT), activated partial thromboplastin time (aPTT), resistance to activated protein C (RAPC), factors VIII and XI, plasminogen activator inhibitor activity (PAI-Fx), protein C antigenic, protein S total (antigenic), protein S free (antigenic), and antithrombin III (functional) ( Table 2 ). The following tests were done in serum: anticardiolipin antibodies, homocysteine, and Lp (a) ( Table 2) .
Statistical Methods
Chi-square or Fisher's exact tests (22) were used for categorical comparisons for PCR and serologic coagulation tests. Wilcoxon tests (22) were used for comparison of ages.
Power calculations were carried out as per Zelterman (23) .
RESULTS
Mean age in the 11 cases was 57 ± 17 years, ranging from 25 to 76 (Table 1) , not different (p =0.5) from the 78 adult controls used for serologic measures (53 ± 18 years). There were eight women and three men, 10 whites and one oriental ( Table 1) . Of the 11 patients, two were obese and one extremely obese ( Table 1) .
None of the 11 cases had connective tissue diseases-lupus erythematosus, and none had antiphospholipid antibody syndrome (Tables 1, 2) . By selection, no cases had abnormal brain MRI, MRA, MRV, atrial fibrillation, or cardiac thrombus (by echocardiography). By selection, no cases had ipsilateral, hemodynamically significant atherosclerotic plaque by carotid and vertebral duplex imaging.
Of the 11 cases, four had treated hypertension, six had treated hyperlipidemia, two smoked, and one had type II diabetes mellitus (Table 1) . One case had a popliteal-femoral bypass procedure, and one had an aortic aneurysm ( Table 1) . No cases had carotid endarterectomy. Three cases had experienced TIA, confirmed by their referring physicians (Table 1) .
Of the eight women, four were receiving exogenous estrogens and one was pregnant ( Table  1) .
All 11 cases had one or more familial thrombophilic and/or hypofibrinolytic coagulation disorder. One case was heterozygous for the G1691A factor V Leiden mutation, two had low free protein S, four had high factor VIII, three had resistance to activated protein C, three were homozygous for the C677T MTHFR mutation, two were compound C677T-A1298C MTHFR heterozygotes, and three had hypofibrinolytic 4G4G homozygosity for the PAI-1 gene ( Table  2 ). Case 10, with high factor VIII (160%), also had two other thrombophilic disorders, com- Bold highlighting for abnormal measures.
pound MTHFR C677T-A1298C heterozygosity and resistance to activated protein C, as well as hypofibrinolytic high Lp(a) ( Table 2) . Thrombophilic C677T MTHFR homozygosity or C677T-A1298C compound MTHFR heterozygosity were present in five of 10 (50%) cases vs. 30 of 248 (12%) controls, Fisher's p [p f ] = .005. With alpha = .05, our study had 92% power to detect the difference in MTHFR mutations between cases and controls. Thrombophilic high factor VIII was present in 4 of 10 cases (40%) vs 0 of 38 (0%) controls (p f = .001). With alpha = .05, our study had 98% power to detect the difference in factor VIII between cases and controls.
No cases had the lupus anticoagulant or antiphospholipid antibody syndrome.
In the four women receiving exogenous estrogens (cases 7, 9, 10, 11) and the pregnant woman (case 2) (Table 1) , there appeared to be interactions between acquired thrombophilia (pregnancy-exogenous estrogens) and heritable thrombophilia-hypofibrinolysis (Tables 1, 2 ). The pregnant case had thrombophilic low total and free protein S (which remained low 3 months post-partum), and was a C677T MTHFR homozygote ( Table 2 ). Case 7 had hypofibrinolytic 4G4G homozygosity and thrombophilic PL AI/A2 heterozygosity for the platelet glycoprotein IIb/IIIa gene ( Table 2 ). Case 9 had three thrombophilic traits (familial low free protein S, familial high factor VIII, thrombophilic resistance to activated protein C) and hypofibrinolytic 4G4G homozygosity for the PAI-1 gene ( Table 2 ). Case 10 had thrombophilic compound C677T-A1298C MTHFR heterozygosity, thrombophilic high factor VIII, thrombophilic resistance to activated protein C, and hypofibrinolytic high Lp(a) ( Table  2 ). Case 11 had thrombophilic C677T MTHFR homozygosity.
DISCUSSION
Amaurosis fugax, a transient monocular loss of vision, usually affecting the entire visual field, has historically been attributed to embolism from ipsilateral carotid atherosclerotic plaque (2) (3) (4) (5) (6) , atrial fibrillation-driven embolism (2-6), endocarditis-coronary thrombus (10), vasospasm (7) , giant cell arteritis (8) , and acquired thrombophilia (antiphospholipid antibodies) (9, 10) . Amaurosis fugax, while itself transient (2) (3) (4) (5) (6) 24) , foretells a high subsequent complication rate (annual blindness rate 1%, annual risk of an ischemic insult 2%, myocardial infarction 30%, 18% mortality rate). Hence, a thorough search for underlying etiologies is important, commonly involving carotid and vertebral duplex imaging, MRI, MRA, MRV, and ophthalmologic, neurologic, serologic (antiphospholipid antibodies), and cardiac evaluation (electrocardiogram, echocardiography). Beyond carotid artery surgery, medical therapy has included fibrinolysis (25) , anticoagulants (26) (27) (28) (29) , and antiplatelet agents (27) (28) (29) . In the presence of genetic thrombophilias (30) as in the current report (G1691A factor V Leiden, high factor VIII (31) (32) (33) (34) , familial protein S deficiency, C677T MTHFR homozygosity, C677T-A1298C MTHFR compound heterozygosity (35) ), antiplatelet agents lack efficacy, and therapy must be based on low-molecular-weight heparin (acutely), warfarin (chronically), and for MTHFR-homocysteine disorders, folic acid, vitamin B6, and vitamin B12 (35) .
As revealed in the current study of cases selected to be free of ipsilateral internal carotid artery plaque, atrial fibrillation, or cardiac thrombi, inherited thrombophilias are associated with and probably cause amaurosis fugax. The association of inherited thrombophilias with amaurosis fugax is not surprising because they cause retinal artery thrombosis (30) and nonarteritic ischemic optic neuropathy (12, 20) . In five of the eight women in this study, thrombophilic exogenous hyperestrogenemia (pregnancy, estrogen replacement therapy) may have interacted with familial thrombophilia-hypofibrinolysis, further promoting thrombus formation (36) . Similar to the interaction of hyperestrogenemia with thrombophilia-hypofibrinolysis (36) promoting amaurosis fugax in this report, Szolnoki and colleagues (37) , in an examination of 867 ischemic stroke patients, reported pairing of "common unfavourable genetic factors" with clinical risk factors which, together, ". . . can greatly increase the susceptibility to ischaemic stroke." We recommend cessation of thrombophilic exogenous estrogens (36) when inherited thrombophilia and hypofibrinolysis are associated with amaurosis fugax, as in the current report.
The current cohort with amaurosis fugax was selected after exclusion of cases with severe ipsilateral carotid plaque, atrial fibrillation, cardiac thrombus, or abnormal brain MRI, MRA, and MRV. In such cases, if the amaurosis fugax is recurrent or is associated with transient cerebral ischemic attacks, provided that there is no contraindication to anticoagulation, consideration should be given to therapeutic enoxaparin anti-coagulation (1 mg/kg every 12 hours subcutaneously), followed by transition to warfarin (under enoxaparin cover if the patient has familial protein C, S, or antithrombin III deficiency).
In the presence of homocysteinemia, or, as in the current report, C677T MTHFR homozygosity or compound C677T-A1298C MTHFR heterozygosity (35) , therapy with folic acid 5 mg, vitamin B6 100 mg, and vitamin B12 2000 mcg/day should ameliorate abnormalities in homocysteine metabolism and protect against the associated thrombophilia. Thromboprophylaxis in cases with amaurosis fugax similar to our cohort may, speculatively, help to prevent the otherwise high risk of later development of amaurosis fugax, retinal artery thrombosis, transient cerebral ischemic attacks, or ischemic strokes (11, (25) (26) (27) (28) (29) , for which amaurosis fugax is a predictive forerunner (2) (3) (4) (5) (6) 24) . We further speculate that inherited thrombophilia-hypofibrinolysis may also augment microembolism from ipsilateral internal carotid artery plaque.
